Table 1.
Table displays patient demographics (age, sex, and ethnicity) for the 72 patients that were completely analyzed. Tumor characteristics included TNM stage and WHO grade. Treatment statistics are shown for RT and chemotherapy. Other induction chemotherapy regimens included combinations of cisplatin, carboplatin, docetaxel, cetuximab, 5-fluorouracil, etoposide, and paclitaxel. Other concurrent chemotherapy regimens included combinations of cisplatin, carboplatin, docetaxel, etoposide, cetuximab, paclitaxel, and erlotinib, unique to certain patients.
| Characteristic | Result |
|---|---|
| Number of patients | 72 |
| Median age at RT completion (SD, range) | 52 (12, 20–77) |
| Sex, n (%) | |
| Female | 15 (21%) |
| Male | 57 (79%) |
| Ethnicity, n (%) | |
| Asian | 10 (14%) |
| Arabic | 2 (3%) |
| Black | 11 (15%) |
| Caucasian | 38 (53%) |
| Hispanic | 10 (14%) |
| Unknown | 1 (1%) |
| TNM stage, n (%) | |
| T1 | 16 (22%) |
| T2 | 13 (18%) |
| T3 | 12 (17%) |
| T4 | 27 (37%) |
| TX | 4 (6%) |
| N0 | 11 (15%) |
| N1 | 17 (24%) |
| N2 | 31 (43%) |
| N3 | 8 (11%) |
| NX | 5 (7%) |
| M0 | 67 (93%) |
| M1 | 5 (7%) |
| WHO grade, n (%) | |
| 1 | 7 (10%) |
| 2 | 26 (36%) |
| 2 to 3 | 6 (8%) |
| 3 | 30 (42%) |
| Unknown | 3 (4%) |
| Dose (Gy), n (%) | |
| 60 | 2 (3%) |
| 66 | 4 (5%) |
| 70 | 66 (91%) |
| 74 | 1 (1%) |
| Fractions, n (%) | |
| 30 | 2 (3%) |
| 32 | 1 (1%) |
| 33 | 61 (85 %) |
| 35 | 8 (11%) |
| IMRT, n (%) | 72 (100%) |
| Induction chemotherapy, n (%) | |
| Yes | 49 (68%) |
| No | 23 (32%) |
| Type, n (%) | |
| TPF | 14 (28%) |
| Cisplatin/docetaxel | 10 (20%) |
| Carboplatin/docetaxel | 6 (12%) |
| Carboplatin/paclitaxel | 5 (10%) |
| TIC | 4 (8%) |
| Modified TPF | 3 (6%) |
| Other | 7 (14%) |
| Concurrent chemotherapy, n (%) | |
| Yes | 63 (87%) |
| No | 9 (13%) |
| Type, n (%) | |
| Cisplatin | 38 (60%) |
| Carboplatin | 16 (25%) |
| Cisplatin/carboplatin | 3 (5%) |
| Other | 6 (10%) |
TPF, docetaxel, cisplatin, fluorouracil; TIC, paclitaxel, ifosfamide, carboplatin.